Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: Clinical usefulness of AGEs as a biomarker for the attenuation of NASH

Journal of Gastroenterology

Volumn 45, Issue 7, 2010, Pages 750-757

  Kimura, Yuki ^a   Hyogo, Hideyuki ^a   Yamagishi, Sho Ichi ^b   Takeuchi, Masayoshi ^c   Ishitobi, Tomokazu ^a   Nabeshima, Yoshitaka ^a   Arihiro, Koji ^a   Chayama, Kazuaki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c HOKURIKU UNIVERSITY   (Japan)

Author keywords

Advanced glycation endproducts; Atorvastatin; Biomarker; NASH with dyslipidemia

Indexed keywords

ADIPONECTIN; ADVANCED GLYCATION END PRODUCT; ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BILIRUBIN; BIOLOGICAL MARKER; CHOLESTEROL; COLLAGEN TYPE 4; FATTY ACID; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; GLYCERALDEHYDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYALURONIC ACID; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; PYRROLE DERIVATIVE; REACTIVE OXYGEN METABOLITE;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BODY MASS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; LABORATORY TEST; LIVER BIOPSY; LOW CARBOHYDRATE DIET; LOW FAT DIET; MALE; METABOLIC PARAMETERS; NONALCOHOLIC FATTY LIVER; OBESITY; OPEN STUDY; ORAL GLUCOSE TOLERANCE TEST; PATIENT COUNSELING; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT REDUCTION; BIOPSY; BLOOD; CLINICAL TRIAL; COMPLICATION; DYSLIPIDEMIAS; FATTY LIVER; GLUCOSE TOLERANCE TEST; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; YOUNG ADULT;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; BIOPSY; BODY MASS INDEX; DYSLIPIDEMIAS; FATTY LIVER; FEMALE; FOLLOW-UP STUDIES; GLUCOSE TOLERANCE TEST; GLYCOSYLATION END PRODUCTS, ADVANCED; HEPTANOIC ACIDS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; REACTIVE OXYGEN SPECIES; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 77955664397     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-010-0203-y     Document Type: Article

References (41)

1. MR Teli OF James AD Burt MK Bennett CP Day 1995 The natural history of nonalcoholic fatty liver: a follow-up study Hepatology 22 1714 1719 10.1002/hep.1840220616 1:STN:280:DyaK28%2FovVyhtQ%3D%3D 7489979
2. S Dam-Larsen M Franzmann IB Andersen P Christoffersen LB Jensen TI Sørensen, et al. 2004 Long term prognosis of fatty liver: risk of chronic liver disease and death Gut 53 750 755 10.1136/gut.2003.019984 1:STN:280:DC%2BD2c3hvVCitQ%3D%3D 15082596 (Pubitemid 38561456)
3. CA Matteoni ZM Younossi T Gramlich N Boparai YC Liu AJ McCullough 1999 Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity Gastroenterology 116 1413 1419 10.1016/S0016-5085(99)70506-8 1:STN:280:DyaK1M3nvVamtw%3D%3D 10348825 (Pubitemid 29258890)
4. O James C Day 1999 Non-alcoholic steatohepatitis: another disease of affluence Lancet 353 1634 1636 10.1016/S0140-6736(99)00163-4 1:STN:280:DyaK1M3ms1yjug%3D%3D 10335777 (Pubitemid 29224514)
5. S Chitturi S Abeygunasekera GC Farrell J Holmes-Walker JM Hui C Fung, et al. 2002 NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome Hepatology 35 373 379 10.1053/jhep.2002.30692 1:CAS:528:DC%2BD38XhsVGrt74%3D 11826411 (Pubitemid 34106377)
6. G Marchesini M Brizi G Bianchi S Tomassetti E Bugianesi M Lenzi, et al. 2001 Nonalcoholic fatty liver disease: a feature of the metabolic syndrome Diabetes 50 1844 1850 10.2337/diabetes.50.8.1844 1:CAS:528:DC%2BD3MXlslKmsr4%3D 11473047
7. JM Hui GC Farrell 2003 Clear messages from sonographic shadows? Links between metabolic disorders and liver disease, and what to do about them J Gastroenterol Hepatol 18 1115 1117 10.1046/j.1440-1746.2003.03170.x 12974896 (Pubitemid 37410039)
8. G Marchesini E Bugianesi G Forlani F Cerrelli M Lenzi R Manini, et al. 2003 Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome Hepatology 37 917 923 10.1053/jhep.2003.50161 12668987 (Pubitemid 36397405)
9. H Hyogo K Iwamoto K Arihiro M Takeuchi T Sato H Ochi, et al. 2007 Elevated levels of serum advanced glycation end products in patients with nonalcoholic steatohepatitis J Gastroenterol Hepatol 22 1114 1119 10.1111/j.1440-1746.2007.04943.x (Pubitemid 47019866)
10. S Yamagishi M Takeuchi Y Inagaki K Nakamura T Imaizumi 2003 Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy Int J Clin Pharmacol Res 23 129 134 1:CAS:528:DC%2BD2cXlvVenu7c%3D 15224502
11. Y Inagaki S Yamagishi T Okamoto M Takeuchi S Amano 2003 Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation Diabetologia 46 284 287 1:CAS:528:DC%2BD3sXhvVyrurg%3D 12627328
12. S Yamagishi Y Inagaki S Amano T Okamoto M Takeuchi Z Makita 2002 Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties Biochem Biophys Res Commun 296 877 882 10.1016/S0006-291X(02)00940-3 1:CAS:528:DC%2BD38XmsV2kurw%3D 12200129
13. C Miele A Riboulet MA Maitan F Oriente C Romano P Formisano, et al. 2003 Human glycated albumin affects glucose metabolism in L6 skeletal muscle cells by impairing insulin-induced insulin receptor substrate (IRS) signaling through a protein kinase C alpha-mediated mechanism J Biol Chem 278 47376 47387 10.1074/jbc.M301088200 1:CAS:528:DC%2BD3sXpt1Cqsbc%3D 12970360 (Pubitemid 37523177)
14. S Yamagishi T Imaizumi 2005 Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy Curr Pharm Des 11 2279 2299 10.2174/1381612054367300 1:CAS:528:DC%2BD2MXlsV2gtL0%3D 16022668 (Pubitemid 40872698)
15. K Iwamoto K Kanno H Hyogo S Yamagishi M Takeuchi S Tazuma K Chayama 2008 Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells J Gastroenterol 43 298 304 10.1007/s00535-007-2152-7 1:CAS:528:DC%2BD1cXlsVOnt78%3D 18458846 (Pubitemid 351650040)
16. H Hyogo S Yamagishi 2008 Advanced glycation end products (AGEs) and their involvement in liver disease Curr Pharm Des 14 969 972 10.2174/ 138161208784139701 1:CAS:528:DC%2BD1cXlslCitrc%3D 18473847 (Pubitemid 351753284)
17. Whalan DJ. The ethics and morality of clinical trials in man. Med J Aust. 1975;1:491-4.
18. H Hyogo S Tazuma K Arihiro K Iwamoto Y Nabeshima M Inoue, et al. 2008 Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia Metabolism 57 1711 1718 10.1016/j.metabol.2008.07.030 1:CAS:528:DC%2BD1cXhtlyktrzP 19013295
19. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2003;26(Suppl 1):S5-20.
20. DR Matthews JP Hosker AS Rudenski BA Naylor DF Treacher RC Turner 1985 Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 412 419 10.1007/BF00280883 1:CAS:528:DyaL2MXlslKnu7k%3D 3899825 (Pubitemid 15018832)
21. M Takeuchi Z Makita R Bucala T Suzuki T Koike Y Kameda 2000 Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo Mol Med 6 114 125 1:CAS:528:DC%2BD3cXktVKltL4%3D 10859028
22. DE Kleiner EM Brunt M Van Natta C Behling MJ Contos OW Cummings, et al. 2005 Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatology 41 1313 1321 10.1002/hep.20701 15915461 (Pubitemid 40770284)
23. Japanese Society for the Study of Obesity 2000 New criteria of obesity (in Japanese) J Jpn Soc Study Obes 6 18 28
24. M Kiyici M Gulten S Gurel SG Nak E Dolar G Savci, et al. 2003 Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis Can J Gastroenterol 17 713 718 14679419
25. A Hatzitolios C Savopoulos G Lazaraki I Sidiropoulos P Haritanti A Lefkopoulos, et al. 2004 Efficacy of omega-3 acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia Indian J Gastroenterol 23 127 128
26. E Gómez-Domínguez JP Gisbert JA Moreno-Monteagudo L García-Buey R Moreno-Otero 2006 A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients Aliment Pharmacol Ther 23 1643 1647 10.1111/j.1365-2036.2006.02926.x 16696815 (Pubitemid 43727474)
27. VG Athyros DP Mikhailidis TP Didangelos OI Giouleme EN Liberopoulos A Karagiannis, et al. 2006 Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study Curr Med Res Opin 22 873 883 10.1185/030079906X104696 1:CAS:528:DC%2BD28XmsFWktr8%3D 16709309 (Pubitemid 43875555)
28. T Funatsu M Goto H Kakuta M Suzuki M Ida S Nishijima, et al. 2002 Reduction in hepatic nonesterified fatty acid concentration after long-term treatment with atorvastatin lowers hepatic triglyceride synthesis and its secretion in sucrose-fed rats Biochim Biophys Acta 1580 161 170 1:CAS:528:DC%2BD38Xjt1Khu70%3D 11880241
29. E Isusi P Aspichueta M Liza ML Hernández C Díaz G Hernández, et al. 2000 Short- and long-term effects of atorvastatin, lovastatin and simvastatin on the cellular metabolism of cholesteryl esters and VLDL secretion in rat hepatocytes Atherosclerosis 153 283 294 10.1016/S0021-9150(00)00407-X 1:CAS:528:DC%2BD3MXlslKqsA%3D%3D 11164417 (Pubitemid 32120327)
30. M Kainuma M Fujimoto N Sekiya K Tsuneyama C Cheng Y Takano, et al. 2006 Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis J Gastroenterol 41 971 980 10.1007/s00535-006-1883-1 1:CAS:528:DC%2BD28XhtFyltLbK 17096066 (Pubitemid 44741410)
31. K Nakamura SI Yamagishi T Matsui H Adachi M Takeuchi T Imaizumi, et al. 2007 Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects Clin Exp Med 7 188 190 10.1007/s10238-007-0146-7 1:STN:280: DC%2BD1c%2FisVCqtA%3D%3D 18188534
32. Yamagishi SI, Matsui T, Adachi H, Takeuchi M. Positive association of circulating levels of advanced glycation end products (AGEs) with pigment epithelium-derived factor (PEDF) in a general population. Pharmacol Res. 2009; doi: 10.1016/j.phrs.2009.07.003.
33. K Nakamura S Yamagishi H Adachi T Matsui Y Kurita-Nakamura M Takeuchi, et al. 2008 Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes Diabetes Metab Res Rev. 24 109 114 10.1002/dmrr.766 1:CAS:528: DC%2BD1cXjtlemsbs%3D 17694504 (Pubitemid 351284754)
34. S Yamagishi S Amano Y Inagaki T Okamoto K Koga N Sasaki, et al. 2002 Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes Biochem Biophys Res Commun 290 973 978 10.1006/bbrc.2001.6312 1:CAS:528:DC%2BD38XksV2juw%3D%3D 11798169 (Pubitemid 34687457)
35. Y Yamamoto I Kato T Doi H Yonekura S Ohashi M Takeuchi, et al. 2001 Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice J Clin Invest 108 261 268 1:CAS:528: DC%2BD3MXlt1Kltrw%3D 11457879
36. Y Yamamoto S Yamagishi H Yonekura T Doi H Tsuji I Kato, et al. 2000 Roles of the AGE-RAGE system in vascular injury in diabetes Ann N Y Acad Sci 902 163 170 1:CAS:528:DC%2BD3cXksFSksr4%3D 10865836 discussion 170-2
37. T Ishitobi H Hyogo S Yamagishi Y Kimura Y Nabeshimai S Tazuma, et al. 2008 Effects of Advanced Glycation End-products and High Glucose on Hepatocytes Jpn Pharmacol Ther 36 189 191
38. Y Jinnouchi S Yamagishi M Takeuchi S Ishida Y Jinnouchi J Jinnouchi T Imaizumi 2006 Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes Clin Exp Med 6 191 193 10.1007/s10238-006-0115-6 1:STN:280:DC%2BD28jltlWguw%3D%3D 17191111 (Pubitemid 46025593)
39. T Nishikawa D Edelstein XL Du S Yamagishi T Matsumura Y Kaneda, et al. 2000 Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage Nature 404 787 790 10.1038/35008121 1:CAS:528: DC%2BD3cXjtVals70%3D 10783895 (Pubitemid 30212409)
40. M Aviram M Rosenblat CL Bisgaier RS Newton 1998 Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation Atherosclerosis 138 271 280 10.1016/S0021-9150(98) 00032-X 1:CAS:528:DyaK1cXksFyjt70%3D 9690910 (Pubitemid 28314098)
41. N Yoshiike H Lwin 2005 Epidemiological aspects of obesity and NASH/NAFLD in Japan Hepatol Res 33 77 82 10.1016/j.hepres.2005.09.008 16226488 (Pubitemid 41799779)